よむ、つかう、まなぶ。
【参考資料6】抗微生物薬適正使用の手引き 第三版 補遺 (39 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
109. Iovleva A, Mustapha MM, Griffith MP. et al. Carbapenem-Resistant Acinetobacter baumannii
in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. mBio.
2022 Apr;13(2):e0275921.
110. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant
Acinetobacter baumannii. J Antimicrob Chemother. 2010 Feb;65(2):233-238.
111. Evans BA, Amyes SG. OXA beta-lactamases. Clin Microbiol Rev. 2014 Apr;27(2):241-263.
112. Lee CR, Lee JH, Park M. et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic
Resistance Mechanisms, and Prospective Treatment Options. Front Cell Infect Microbiol.
2017 Mar;7:55.
113. Yamamoto M, Nagao M, Matsumura Y. et al. Interspecies dissemination of a novel class 1
integron carrying blaIMP-19 among Acinetobacter species in Japan. J Antimicrob Chemother.
2011 Nov;66(11):2480-2483.
114. Akeda Y. Current situation of carbapenem-resistant Enterobacteriaceae and Acinetobacter in
Japan and Southeast Asia. Microbiol Immunol. 2021 Jun;65(6):229-237.
115. Matsui M, Suzuki M, Suzuki M. et al. Distribution and Molecular Characterization of
Acinetobacter baumannii International Clone II Lineage in Japan. Antimicrob Agents
Chemother. 2018 Jan;62(2):e02190-17.
116. 薬剤耐性アシネトバクター感染症. at https://www.mhlw.go.jp/bunya/kenkou/kekkakukansenshou11/01-05-140912-4.html.)
117. 国立感染症研究所 感染症法に基づく薬剤耐性アシネトバクター感染症の届出状況. 2019. at
https://www.niid.go.jp/niid/ja/mdra-m/mdra-idwrs/10322-mdra-210423.html.)
118. 厚生労働省 院内感染対策サーベイランス 薬剤耐性菌 判定基準（Ver.3.2）. 2019. at
https://janis.mhlw.go.jp/section/standard/drugresistancestandard_ver3.2_20190109.pdf.)
119. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter
baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019 Aug;25(8):951-957.
120. Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC. Antibiotic strategies and clinical
outcomes in critically ill patients with pneumonia caused by carbapenem-resistant
Acinetobacter baumannii. Clin Microbiol Infect. 2018 Aug;24(8):908.e1-908.e7.
121. Chuang YC, Cheng CY, Sheng WH. et al. Effectiveness of tigecycline-based versus colistinbased therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter
baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014 Feb;14:102.
122. Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N.
Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter
baumannii infections: a systematic review and network meta-analysis. J Antimicrob
Chemother. 2018 Jan;73(1):22-32.
123. Government of South Australia. Staphylococcus aureus Bacteraemia Management Clinical
Guideline Version 2.0. 2023.
124. Kwon KH, Oh JY, Yoon YS. et al. Colistin treatment in carbapenem-resistant Acinetobacter
baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes. Int J Antimicrob
Agents. 2015 Jun;45(6):605-609.
39
in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. mBio.
2022 Apr;13(2):e0275921.
110. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant
Acinetobacter baumannii. J Antimicrob Chemother. 2010 Feb;65(2):233-238.
111. Evans BA, Amyes SG. OXA beta-lactamases. Clin Microbiol Rev. 2014 Apr;27(2):241-263.
112. Lee CR, Lee JH, Park M. et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic
Resistance Mechanisms, and Prospective Treatment Options. Front Cell Infect Microbiol.
2017 Mar;7:55.
113. Yamamoto M, Nagao M, Matsumura Y. et al. Interspecies dissemination of a novel class 1
integron carrying blaIMP-19 among Acinetobacter species in Japan. J Antimicrob Chemother.
2011 Nov;66(11):2480-2483.
114. Akeda Y. Current situation of carbapenem-resistant Enterobacteriaceae and Acinetobacter in
Japan and Southeast Asia. Microbiol Immunol. 2021 Jun;65(6):229-237.
115. Matsui M, Suzuki M, Suzuki M. et al. Distribution and Molecular Characterization of
Acinetobacter baumannii International Clone II Lineage in Japan. Antimicrob Agents
Chemother. 2018 Jan;62(2):e02190-17.
116. 薬剤耐性アシネトバクター感染症. at https://www.mhlw.go.jp/bunya/kenkou/kekkakukansenshou11/01-05-140912-4.html.)
117. 国立感染症研究所 感染症法に基づく薬剤耐性アシネトバクター感染症の届出状況. 2019. at
https://www.niid.go.jp/niid/ja/mdra-m/mdra-idwrs/10322-mdra-210423.html.)
118. 厚生労働省 院内感染対策サーベイランス 薬剤耐性菌 判定基準（Ver.3.2）. 2019. at
https://janis.mhlw.go.jp/section/standard/drugresistancestandard_ver3.2_20190109.pdf.)
119. Piperaki ET, Tzouvelekis LS, Miriagou V, Daikos GL. Carbapenem-resistant Acinetobacter
baumannii: in pursuit of an effective treatment. Clin Microbiol Infect. 2019 Aug;25(8):951-957.
120. Liang CA, Lin YC, Lu PL, Chen HC, Chang HL, Sheu CC. Antibiotic strategies and clinical
outcomes in critically ill patients with pneumonia caused by carbapenem-resistant
Acinetobacter baumannii. Clin Microbiol Infect. 2018 Aug;24(8):908.e1-908.e7.
121. Chuang YC, Cheng CY, Sheng WH. et al. Effectiveness of tigecycline-based versus colistinbased therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter
baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis. 2014 Feb;14:102.
122. Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N.
Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter
baumannii infections: a systematic review and network meta-analysis. J Antimicrob
Chemother. 2018 Jan;73(1):22-32.
123. Government of South Australia. Staphylococcus aureus Bacteraemia Management Clinical
Guideline Version 2.0. 2023.
124. Kwon KH, Oh JY, Yoon YS. et al. Colistin treatment in carbapenem-resistant Acinetobacter
baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes. Int J Antimicrob
Agents. 2015 Jun;45(6):605-609.
39